Business · 30/03/2023Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product
Summary
The FDA has awarded a priority review voucher to Acadia Pharmaceuticals, Inc. for its rare pediatric disease product DAYBUE, which was approved on March 10, 2023.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →